AR060614A1 - Derivados de dicarboxamida - Google Patents

Derivados de dicarboxamida

Info

Publication number
AR060614A1
AR060614A1 ARP070101697A ARP070101697A AR060614A1 AR 060614 A1 AR060614 A1 AR 060614A1 AR P070101697 A ARP070101697 A AR P070101697A AR P070101697 A ARP070101697 A AR P070101697A AR 060614 A1 AR060614 A1 AR 060614A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
alkyl
carbonyl
heterocyclyl
heteroaryl
Prior art date
Application number
ARP070101697A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36942280&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR060614(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR060614A1 publication Critical patent/AR060614A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a derivados de dicarboxamida, y una composicion farmacéutica en base a ellos. Estos compuestos inhiben el factor de coagulacion Xa y pueden utilizarse como medicamentos, en trastornos cardiovasculares, inflamacion y aterosclerosis. Reivindicacion 1: Compuestos con la formula (1) en los que R2 y R3 son independientemente el uno del otro hidrogeno, alquilo C1-6, carboxilo, alcoxicarbonilo C1-6, carbamoilo, amino-carbonilo mono- o disustituido, aril carbonilo opcionalmente sustituido, heterociclilcarbonilo opcionalmente sustituido, heteroarilcarbonilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heterociclilo opcionalmente sustituido, hidroxil-alquilo C1- 6, halo-alquilo C1-6, ciano-alquilo C1-6, alcoxi C1-6-alquilo C1-6, amino-alquilo C1-6, amino-alquilo C1-6 mono- o di-sustituido, aril-alquilo C1-6 opcionalmente sustituido, heterociclil alquilo C1-6 opcionalmente sustituido, heteroaril alquilo C1-6 opcionalmente sustituido, aril alcoxi C1-6 alquilo C1-6 opcionalmente sustituido, heteroaril alcoxi C1-6 alquilo C1-6 opcionalmente sustituido, heterociclil alcoxi C1-6 alquilo C1-6 opcionalmente sustituido, R1 y R4 son, independientemente el uno del otro hidrogeno, alquilo C1-6, ciano, alcoxicarbonilo C1-6, alqueniloxicarbonilo C2-6, alquiniloxicarbonilo C2-6, hidroxil alquilo C1-6, alcoxicarbonilo C1-6, carboxilo, amino-carbonilo mono- o di- alquilo C1-6 sustituido, aminocarbonilo, heterociclil carbonilo opcionalmente sustituido, heteroaril carbonilo opcionalmente sustituido o aril carbonilo opcionalmente sustituido, R5 y R6 son, independientemente el uno del otro, cloro, fluor o bromo; o sales farmacéuticamente aceptables de los mismos.
ARP070101697A 2006-04-21 2007-04-19 Derivados de dicarboxamida AR060614A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06112897A EP1847537A1 (en) 2006-04-21 2006-04-21 Dicarboxamide derivatives

Publications (1)

Publication Number Publication Date
AR060614A1 true AR060614A1 (es) 2008-07-02

Family

ID=36942280

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101697A AR060614A1 (es) 2006-04-21 2007-04-19 Derivados de dicarboxamida

Country Status (14)

Country Link
US (2) US20070249683A1 (es)
EP (2) EP1847537A1 (es)
JP (1) JP2009534347A (es)
KR (1) KR20080109866A (es)
CN (1) CN101421242B (es)
AR (1) AR060614A1 (es)
AU (1) AU2007242884A1 (es)
BR (1) BRPI0710539A2 (es)
CA (1) CA2649458A1 (es)
CL (1) CL2007001091A1 (es)
IL (1) IL194555A0 (es)
MX (1) MX2008013225A (es)
TW (1) TW200811136A (es)
WO (1) WO2007122104A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550487B2 (en) * 2004-03-26 2009-06-23 Hoffmann-La Roche Inc. Pyrrolidine-3,4-dicarboxamide derivatives
EP1814855B1 (en) * 2004-11-03 2011-01-19 F. Hoffmann-La Roche AG Dicarboxamide derivatives and their use as factor xa inhibitors
RU2439065C2 (ru) 2006-04-20 2012-01-10 Ф.Хоффманн-Ля Рош Аг Производные диазепана в качестве модуляторов хемокиновых рецепторов
US9809545B2 (en) 2013-03-27 2017-11-07 Merck Sharp & Dohme Corp. Factor XIa inhibitors
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2341542A1 (en) * 1999-06-24 2000-12-28 Toray Industries, Inc. .alpha.1b-adrenergic receptor antagonists
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
AU2003279735A1 (en) * 2002-10-02 2004-04-23 Bristol-Myers Squibb Company Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor xa inhibitors
JP2004210716A (ja) * 2002-12-27 2004-07-29 Dai Ichi Seiyaku Co Ltd ジアミド誘導体
EP1814855B1 (en) * 2004-11-03 2011-01-19 F. Hoffmann-La Roche AG Dicarboxamide derivatives and their use as factor xa inhibitors

Also Published As

Publication number Publication date
EP2013177A1 (en) 2009-01-14
KR20080109866A (ko) 2008-12-17
US20070249683A1 (en) 2007-10-25
WO2007122104A1 (en) 2007-11-01
IL194555A0 (en) 2009-08-03
TW200811136A (en) 2008-03-01
BRPI0710539A2 (pt) 2011-08-16
CA2649458A1 (en) 2007-11-01
JP2009534347A (ja) 2009-09-24
US20110195997A1 (en) 2011-08-11
CL2007001091A1 (es) 2008-01-04
CN101421242A (zh) 2009-04-29
CN101421242B (zh) 2011-06-01
EP1847537A1 (en) 2007-10-24
AU2007242884A1 (en) 2007-11-01
MX2008013225A (es) 2008-10-21

Similar Documents

Publication Publication Date Title
ES2521596T3 (es) Combinación del compuesto GlyT1 con antipsicóticos
AR060614A1 (es) Derivados de dicarboxamida
SG148178A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
CL2009000882A1 (es) Un compuesto n-(4-cloro-3-(piridin-2-il)fenil)-4-(2-hidroxi-2-metilpropilsulfonil)-2-metilbenzamida, inhibidor de la via de señalización hedgehog; composición farmacéutica que comprende a dicho compuesto; y su uso para tratar el cancer.
CO6220939A2 (es) Derivados de 4-(fenilamino) quinolina-3-carboxamida con actividad anticancerigena
DE602004023207D1 (de) Benzimidazol-derivate als mek-hemmer
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
MX2009004441A (es) Derivados de indazol utiles como inhibidores de las isoformas de higado.
CY1118662T1 (el) Νεες δικυκλικες πυριδινονες
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
AR076258A1 (es) Agentes antihelminticos y su utilizacion
CR10027A (es) Nuevos derivados de pirrol fusionado
MX2010005824A (es) Derivados de aminotiazol.
PE20091400A1 (es) Derivados de n-(2-amino-fenil)-amida como inhibidores de hdac
ATE519764T1 (de) Spiroindolinon-derivate
AR062797A1 (es) Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas.
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
UY31986A (es) Derivados n- sustituídos de la 2-metil-propionamida;{1-[5-sustiuido-4-sustituido-tiazol-2-il-carbamoil]-1-metil-etil} amidas de ácidos carboxílicos sustituidos, derivados farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
ECSP088229A (es) Derivados de pirazolona como inhibidores de 11-beta hsd1
TW200616958A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
DOP2012000050A (es) Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil] piperazina
EA201190320A1 (ru) Гетероциклические сульфонамиды, их применения и фармацевтические композиции
BR112015011974A2 (pt) derivados de azaquinazolina carboxamida
NI201200070A (es) Nueva asociación entre la 4 - {3 - [cis -hexahidrociclopenta [c] pirrol - 2 (1h)- il] propoxi} benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmacéuticas que la contienen.
MX2010005164A (es) Derivados de bencimidazol y su uso como agonistas del receptor x de farnesoide.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal